Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Oats1件: Oat---1件: 97
2OAV101----1件: 3
3Obatoclax1件: Obatoclax---1件: 60
4Obatoclax mesylate (GX15-070MS)1件: Obatoclax---1件: 60
5Obeticholic Acid1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬3件: 93, 265, 296
6Obeticholic Acid (OCA)1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
7Obeticholic Acid 5 MG1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
8Obeticholic Acid Tablets1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
9OBI-1----1件: 288
10OBINUTUZUMAB1件: Obinutuzumab1件: D09321 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 49, 222
11Obinutuzumab administration1件: Obinutuzumab1件: D09321 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49
12OBINUTUZUMAB/ GA1011件: Obinutuzumab1件: D09321 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222
13Obitunuzumab----1件: 222
14OBIZUR1件: Susoctocog alfa1件: D10831 --1件: 288
15Observational study----2件: 46, 271
16Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag		5件: D00106 ,
D01337 ,
D02721 ,
D09994 ,
D10135 		3件: EDNRA,
EDNRB,
PTGIR 💬		10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
17Obyoctocog alfa----1件: 288
18OC oral solution treatment A----1件: 6
19OC oral solution treatment B----1件: 6
20OC oral solution treatment C----1件: 6
21OC oral solution treatment D----1件: 6
22OC000459----1件: 98
23OCA----2件: 94, 296
24OCA (INT-747)----1件: 93
25OCA 0.1 mg----1件: 296
26OCA 1,5 mg----1件: 94
27OCA 1.5mg----1件: 296
28OCA 5 mg----1件: 94
29OCA 5mg----1件: 296
30OCA, INT-747----1件: 93
31Ocaliva1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬2件: 93, 296
32Ocaliva 10mg1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
33Ocaliva 5mg1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
34Occlusive non adherent dressing----1件: 36
35OCH-NCNP1----1件: 13
36Oclelizumab----1件: 13
37OCR----1件: 13
38OCRELIZUMAB1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬3件: 13, 46, 49
39Ocrelizumab (CinnaGen, Iran)1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
40Ocrelizumab (Roche, Switzerland)1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
41Ocrelizumab / rhuMAb 2H71件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
42Ocrelizumab 300 mg1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
43Ocrelizumab 300mg1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
44Ocrelizumab 300mg /10ml1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
45Ocrelizumab 300mg/10 ml1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
46Ocrelizumab 300mg/10ml1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
47Ocrelizumab 500mg1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
48Ocrelizumab 600 mg1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
49Ocrelizumab at home1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
50Ocrelizumab Dose 11件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
51Ocrelizumab Dose 2 and Dose 31件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
52Ocrelizumab IV1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
53Ocrelizumab SC1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
54Ocrelizumabu 200mg----1件: 46
55Ocrelizumabu 50mg----1件: 46
56OCREVUS1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
57Ocrevus 300 mg, solution à diluer pour perfusion1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
58Ocrrelizumab 300 mg----1件: 13
59OCT - TCE----1件: 6
60OCTA-C1-INH1件: Human C1-esterase inhibitor---1件: 65
61OctaAlpha1----1件: 231
62Octagam----2件: 13, 65
63Octagam 10%----3件: 50, 63, 65
64Octagam 5%----2件: 13, 65
65Octagam 50 mg/ml----1件: 13
66OCTAGAM 50 mg/ml oldatos infúzió----1件: 65
67Octagam® 10%----1件: 63
68Octanate1件: Beroctocog alfa---1件: 288
69OCTANATE 100 UI/ml, poudre et solvant pour solution injectable1件: Beroctocog alfa---1件: 288
70OCTANATE 50 UI/ml, poudre et solvant pour solution injectable1件: Beroctocog alfa---1件: 288
71Octanorm----2件: 50, 65
72Octanorm 16.5%----2件: 50, 65
73Octaplas1件: Plasma protein fraction (human)---1件: 64
74Octaplas infusion1件: Plasma protein fraction (human)---1件: 64
75Octaplas SD1件: Plasma protein fraction (human)---1件: 64
76OctaplasLG®----1件: 64
77Octaplas®LG1件: Plasma protein fraction (human)---1件: 64
78Octeotride----1件: 67
79OCTOCOG ALFA1件: Antihemophilic factor, human recombinant1件: D02958 --1件: 288
80Octostim----2件: 64, 288
81Octreotide1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬7件: 67, 75, 84, 85, 89, 193, 227
82Octreotide a azione pronta 0,1 mg1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 227
83OCTREOTIDE ACETATE2件: Acetate,
Octreotide		2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 227
84OCTREOTIDE ACETATO1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 227
85Octreotide LAR1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬2件: 67, 227
86Octreotide LAR / Sandostatin LAR (LAR=long acting release)1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84
87Octreotide-LAR1件: Octreotide2件: D00442 ,
D06495 		1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 67
88OCU400 High Dose----1件: 90
89OCU400 Low Dose----1件: 90
90OCU400 Mid Dose----1件: 90
91Ocufolin----1件: 13
92Odevixibat1件: Odevixibat1件: D11716 1件: SLC10A2 💬1件: Bile secretion 💬3件: 296, 297, 338
93Odiparcil1件: Odiparcil---1件: 19
94ODM-101----1件: 6
95ODM-101 105mg Carbidopa1件: Carbidopa1件: D00558 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
96ODM-101 65mg Carbidopa1件: Carbidopa1件: D00558 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
97ODM-104----1件: 6
98ODM-109----1件: 2
99ODM-109 capsule 1 mg----1件: 2
100ODSH at 0.125 mg/kg/h----1件: 210
101ODSH at 0.250 mg/kg/h----1件: 210
102ODSH at 0.375 mg/kg/h----1件: 210
103Oestrogen----1件: 78
104OFATUMUMAB1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬3件: 13, 35, 46
105Ofatumumab 1001件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
106Ofatumumab 3001件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
107Ofatumumab 30mg1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
108Ofatumumab 3mg1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
109Ofatumumab 60mg1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
110Ofatumumab 7001件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
111Ofatumumab subcutaneous injection1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
112Ofev1件: Nintedanib1件: D10481 8件: FGFR1,
FGFR2,
FGFR3,
FLT1,
FLT4,
KDR,
PDGFRA,
PDGFRB 💬		34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬5件: 51, 85, 89, 227, 228
113Ofev 100 mg capsule1件: Nintedanib1件: D10481 8件: FGFR1,
FGFR2,
FGFR3,
FLT1,
FLT4,
KDR,
PDGFRA,
PDGFRB 💬		34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬1件: 85
114Ofev 150 mg capsule1件: Nintedanib1件: D10481 8件: FGFR1,
FGFR2,
FGFR3,
FLT1,
FLT4,
KDR,
PDGFRA,
PDGFRB 💬		34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬1件: 85
115OFEV®----1件: 85
116OFF Dopaminergic Medication----1件: 6
117OGT 918----2件: 19, 299
118OGT918----1件: 19
119OGT923----1件: 19
120OK432----1件: 278
121Okrido----1件: 3
122Okrido 6mg/mL oral solution----1件: 3
123Oksikodoni----1件: 70
124OL adalimumab 40 mg1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
125OLANZAPINE1件: Olanzapine2件: D00454 ,
D06623 		11件: ADRA1A,
ADRA1B,
ADRA1D,
DRD2,
DRD3,
DRD4,
HRH1,
HTR2A,
HTR2B,
HTR2C,
HTR6 💬		16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 2, 8
126Olaparib1件: Olaparib1件: D09730 2件: PARP1,
PARP2 💬		5件: Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis 💬2件: 86, 285
127OLE BSA Adalimumab +/- MTX1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
128OLE FD Adalimumab +/- MTX1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
129Oleic Acid1件: Oleic Acid1件: D02315 --2件: 13, 299
130Oleic acid supplementation1件: Oleic Acid1件: D02315 --1件: 299
131OLENASUFLIGENE RELDUPARVOVEC1件: Olenasufligene relduparvovec---1件: 19
132Oleogel-S10----1件: 36
133Oleovit D3 14.400 IU/ml oral drops, solution----1件: 13
134Olesoxime----2件: 2, 3
135Olesoxime (TRO19622)1件: TRO19622---1件: 13
136Oligofructose enriched inulin1件: Inulin1件: D00171 --1件: 96
137OligoG----1件: 299
138OligoG (60 mg/ml)----1件: 299
139OLIGOG CF-5/20----1件: 299
140OligoG CF-5/20 - 17.5 mg----1件: 299
141OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299
142OligoG CF/20 - 27.5 mg----1件: 299
143OligoG CF/20 - 37.5 mg----1件: 299
144OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299
145OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299
146OligoG DPI----1件: 299
147OligoG Dry powder for inhalation----1件: 299
148OligoG-CF5/20, Alginate oligosaccharide (G-block) fragment1件: Alginic acid1件: D02324 --1件: 299
149Oligomer of Sodium Alginate1件: Alginic acid1件: D02324 --1件: 299
150Oligomero morfolino fosforodiamidato per skipping dell’esone 45----1件: 113
151Oligomero morfolino fosforodiamidato per skipping dell’esone 53----1件: 113
152Olikizumab----1件: 46
153Olipudase alfa1件: Olipudase alfa1件: D10820 1件: SMPD1 💬5件: Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway 💬1件: 19
154Olipudase alfa (rhASM)1件: Olipudase alfa1件: D10820 1件: SMPD1 💬5件: Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway 💬1件: 19
155Olive1件: Olea europaea leaf---3件: 13, 49, 53
156Olive oil2件: Olea europaea leaf,
Olive oil		1件: D03311 --3件: 13, 49, 53
157Olokizumab1件: Olokizumab---2件: 46, 96
158Olokizumab (OKZ)1件: Olokizumab---1件: 96
159Olokizumab 120 mg1件: Olokizumab---1件: 46
160Olokizumab 240 mg1件: Olokizumab---1件: 46
161Olokizumab 60 mg1件: Olokizumab---1件: 46
162Olokizumab 64 mg SC q2w1件: Olokizumab---1件: 46
163Olokizumab 64 mg SC q4w1件: Olokizumab---1件: 46
164Olokizumab 64mg q2w1件: Olokizumab---1件: 46
165Olokizumab 64mg q4w1件: Olokizumab---1件: 46
166Olokizumab q2w1件: Olokizumab---1件: 46
167Olokizumab q4w1件: Olokizumab---1件: 46
168Olsalazine1件: Olsalazine2件: D00727 ,
D08295 		--1件: 271
169Olumiant1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬4件: 46, 49, 93, 107
170Olumiant - EU/1/16/1170/001-0081件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 49
171Olumiant - EU/1/16/1170/009-0161件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 49
172OLUMIANT 4 mg1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
173OLUMIANT 4mg1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
174Oluminant----1件: 107
175OM 89.----1件: 46
176Omacor----1件: 49
177Omadacycline1件: Omadacycline1件: D09647 --1件: 299
178Omadacycline Injection [Nuzyra]1件: Omadacycline1件: D09647 --1件: 299
179Omadacycline Oral Tablet [Nuzyra]1件: Omadacycline1件: D09647 --1件: 299
180OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
181Omalizumab (Xolair)1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 65
182Omaveloxolone1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
183Omaveloxolone Capsules, 10 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
184Omaveloxolone Capsules, 150 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
185Omaveloxolone Capsules, 160 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
186Omaveloxolone Capsules, 2.5 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
187Omaveloxolone Capsules, 20 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
188Omaveloxolone Capsules, 300 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
189Omaveloxolone Capsules, 40 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
190Omaveloxolone Capsules, 5 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
191Omaveloxolone Capsules, 80 mg1件: Omaveloxolone1件: D10964 1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18
192OMB 157----1件: 13
193OMB157----1件: 13
194OMB157G----1件: 13
195Omega 3----3件: 13, 53, 299
196Omega 3 fatty acid----1件: 53
197Omega 3 fatty acids1件: Omega-3 fatty acids---1件: 13
198Omega 3 Premium----1件: 299
199Omega-31件: Omega-3 fatty acids---7件: 13, 46, 49, 66, 79, 96, 299
200Omega-3 and Vitamin E supplementation2件: Omega-3 fatty acids,
Vitamin E		1件: D02331 --1件: 46
201Omega-3 fatty acid1件: Omega-3 fatty acids---2件: 46, 66
202Omega-3 fatty acid ethylester901件: Omega-3 fatty acids---1件: 66
203Omega-3 Fatty Acid Fish Oil Supplement2件: Fish oil,
Omega-3 fatty acids		---1件: 66
204Omega-3 fatty acids1件: Omega-3 fatty acids---2件: 13, 79
205Omega-3 triglycerides1件: Omega-3 fatty acids---1件: 299
206OMEGA-3-ACID TRIGLYCERIDES1件: Omega-3 fatty acids---1件: 299
207Omega3----1件: 46
208Omegaven----1件: 96
209Omegaven (10% fish-oil emulsion----1件: 46
210Omegaven 10%----1件: 96
211Omeprazol1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 294
212Omeprazole1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
213Omeprazole (UK licensed generic product)1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 85
214Omeprazole 20 mg1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 96, 97
215Omeprazole 20 MG Oral Tablet1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
216Omeprazole 20mg1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 51
217Omeprazole 20mg BID1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98
218Omeprazole 40 mg1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 96
219Omeprazole 40mg Capsule1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 299
220OMEPRAZOLE MAGNESIUM2件: Magnesium,
Omeprazole		4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 225
221Omeprazole rectally 1mg/kg1件: Omeprazole4件: D00455 ,
D01207 ,
D05259 ,
D05261 		2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 294
222Omigapil1件: Omigapil---1件: 113
223Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)1件: Methamidophos---1件: 118
224OMNIPAQUE1件: Iohexol1件: D01817 --2件: 19, 222
225OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML1件: Iohexol1件: D01817 --1件: 222
226Omnitrop----1件: 78
227OMNITROPE1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬2件: 78, 193
228Omnitrope®1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
229OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬1件: 109
230OMS643762----1件: 8
231OMS721----3件: 64, 66, 109
232OMS721 (narsoplimab)1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 66, 222
233OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
234OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
235OMS721 Drug Product 185 mg/mL----1件: 109
236ON 01910.NA----1件: 36
237ON Dopaminergic Medication----1件: 6
238Onabotulinum Toxin A----1件: 226
239Onabotulinumtoxin A----2件: 51, 226
240Onabotulinumtoxin A Injection----1件: 6
241OnabotulinumtoxinA1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬3件: 6, 13, 226
242ONASEMNOGENE ABEPARVOVEC1件: Onasemnogene abeparvovec1件: D11559 1件: SMN1 💬-1件: 3
243Onasemnogene Abeparvovec-xioi1件: Onasemnogene abeparvovec1件: D11559 1件: SMN1 💬-1件: 3
244Once a day Trientine1件: Triethylenetetramine---1件: 171
245Once daily subcutaneous injection of Genotropin1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
246Once weekly subcutaneous injection of TransCon hGH----1件: 78
247Once-daily insulin detemir1件: Insulin detemir1件: D04539 1件: INSR 💬22件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 299
248Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter2件: Iodide,
Sodium iodide		3件: D04874 ,
D05328 ,
D05863 		--1件: 34
249Oncovin----1件: 34
250Oncoxin + Viusid----1件: 46
251Ondansetron1件: Ondansetron2件: D00456 ,
D00678 		5件: HTR3A,
HTR3B,
HTR3C,
HTR3D,
HTR3E 💬		2件: Serotonergic synapse, Taste transduction 💬4件: 6, 97, 107, 231
252Ondansetron 8 mg film-coated tablets1件: Ondansetron2件: D00456 ,
D00678 		5件: HTR3A,
HTR3B,
HTR3C,
HTR3D,
HTR3E 💬		2件: Serotonergic synapse, Taste transduction 💬1件: 6
253Ondansetron hydrochloride dihydrate1件: Ondansetron2件: D00456 ,
D00678 		5件: HTR3A,
HTR3B,
HTR3C,
HTR3D,
HTR3E 💬		2件: Serotonergic synapse, Taste transduction 💬2件: 6, 97
254One additional blood sample during a planned blood test----1件: 266
255One Alpha----2件: 50, 107
256One Alpha Drops----2件: 50, 107
257One-alpha1件: Alfacalcidol1件: D01518 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬2件: 50, 107
258One-Alpha drops1件: Alfacalcidol1件: D01518 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬2件: 50, 107
259Ongentys1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
260Ongentys 50 mg capsule rigide1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
261Ongentys 50 mg hard capsules1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
262Ongentys 50mg1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
263Only 1 arm: treatment with MSC-AFP----1件: 96
264Only medicinal products registered in Austria will be used in this clinical trial.----1件: 78
265Only medicinal products registered in Germany will be used in this clinical trial----1件: 78
266ONO-2160/CD----1件: 6
267ONO-2370----1件: 6
268ONO-2506----1件: 2
269ONO-2506PO----2件: 2, 6
270ONO-4059----1件: 35
271ONO-4641----1件: 13
272ONO-4641/ MSC2430913A----1件: 13
273ONO-4641/MSC2430913A----1件: 13
274Ontamalimab1件: Ontamalimab---2件: 96, 97
275OP-724----1件: 93
276Opana1件: Oxymorphone1件: D08323 1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 70
277OPC----1件: 6
278OPC-41061----1件: 67
279OPC-41061 (tolvaptan)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
280OPC-6535----2件: 96, 97
281OPC-6535 Tablets (drug)----1件: 97
282OPC-6535(Tetomilast)1件: Tetomilast---2件: 96, 97
283Open Label (Avatrombopag tablets)1件: Avatrombopag1件: D10306 1件: MPL 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 63
284Open label - AL001----1件: 127
285Open label RAD001 (only used for post-extension phase)----1件: 158
286Open Label Topical Beremagene Geperpavec (B-VEC)----1件: 36
287Open-label Abatacept1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
288Open-label Adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
289Open-Label CDCA 250 mg TID1件: Chenodeoxycholic acid1件: D00163 1件: NR1H4 💬1件: Bile secretion 💬1件: 263
290Open-label PTH(1-84)----1件: 235
291Open-labelAdalimumabRescue----1件: 46
292Ophthalmic Emulsion----2件: 51, 53
293Ophthalmologic evaluation----1件: 78
294Ophthalmology exam----1件: 19
295OPICAPONE1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
296Opicapone (OPC)1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
297Opicapone 50 mg1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
298Opicapone 50 mg hard capsules1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
299Opicinumab1件: Opicinumab1件: D11767 1件: LINGO1 💬-1件: 13
300OPL-CCL2-LPM----1件: 66
301Oprelvekin1件: Oprelvekin1件: D05266 1件: IL11RA 💬3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬1件: 288
302Oprelvekin, Interleukin 11, IL-111件: Oprelvekin1件: D05266 1件: IL11RA 💬3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬1件: 288
303OPRX-106----1件: 97
304OPRX-106 (plant cells expressing TNFR-Fc) 2mg----1件: 97
305OPRX-106 (plant cells expressing TNFR-Fc) 8mg----1件: 97
306OPS-2071----1件: 96
307OPS-2071 150 mg----1件: 96
308OPS-2071 300 mg----1件: 96
309OPS-2071 600 mg----1件: 96
310Opsumit1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
311Opsumit (macitentan)1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
312Opsumit 10 Mg Tablet----1件: 51
313Opsumit®1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
314Optical coherence tomography (OCT)----1件: 13
315Optical coherence tomography angiography (OCTA)----1件: 13
316Optimal drug therapy----1件: 6
317Optimized antiparkinsonian treatment----1件: 6
318Optimized oral treatment----1件: 6
319Optinate 5 mg filmcoated tablets----1件: 274
320Optison1件: Perflutren1件: D01738 --1件: 96
321Optivate----1件: 288
322Optivate® (Human Coagulation Factor VIII)1件: Antihemophilic factor human---1件: 288
323Oral----2件: 46, 271
324Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone2件: Mesalazine,
Methylprednisolone		7件: D00377 ,
D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
325Oral all-trans retinoic acid (ATRA)1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 94
326Oral anticoagulant treatment----1件: 86
327Oral Aztreonam1件: Aztreonam2件: D00240 ,
D06558 		--1件: 299
328Oral bovine type I collagen1件: Bovine type I collagen---1件: 51
329Oral bovine type II collagen----1件: 46
330Oral Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
331Oral Budesonide Suspension (MB-9)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
332Oral Budesonide Suspension (OBS)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
333Oral ciprofloxacin1件: Ciprofloxacin2件: D00186 ,
D02216 		--1件: 299
334Oral ciprofloxacin plus inhaled colistin2件: Ciprofloxacin,
Colistin		4件: D00186 ,
D02138 ,
D02216 ,
D07746 		--1件: 299
335Oral corticosteroids----4件: 13, 46, 97, 171
336Oral corticosteroids (OCS)----1件: 162
337Oral cromolyn sodium1件: Cromoglicic acid2件: D00526 ,
D07753 		--1件: 98
338Oral Cyclosporine1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222
339Oral drops solution----1件: 28
340Oral ERA----1件: 86
341Oral erythromycin1件: Erythromycin9件: D00140 ,
D00851 ,
D01361 ,
D02009 ,
D02184 ,
D02523 ,
D02524 ,
D02525 ,
D04054 		--1件: 36
342Oral escitalopram1件: Escitalopram3件: D02567 ,
D07704 ,
D07913 		1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬1件: 6
343Oral Glucose Tolerance Test1件: Dextrose, unspecified form---1件: 299
344Oral Glucose Tolerance test (75g 2-hour)1件: Dextrose, unspecified form---1件: 299
345Oral Glutathione1件: Glutathione2件: D00014 ,
D00031 		--1件: 299
346Oral Ifetroban1件: Ifetroban1件: D04500 1件: TBXA2R 💬3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation 💬2件: 51, 86
347Oral Iron1件: Iron---2件: 97, 254
348Oral levodopa and carbidopa2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
349Oral Levodopa/Carbidopa2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
350Oral LEVOSIMENDAN1件: Levosimendan1件: D04720 2件: PDE3A,
PDE3B 💬		11件: Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 2
351Oral lipoic acid (LA)1件: Lipoic acid2件: D00048 ,
D00086 		--1件: 13
352Oral methotrexate1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
353Oral Methylprednisolone 625 mg/24h x3 days1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 13
354Oral migalastat HCl1件: Migalastat1件: D10359 --1件: 19
355Oral nutritional supplementation----1件: 2
356Oral OKT3----1件: 97
357Oral PDE5 inhibitors----1件: 86
358Oral Pednisolone----1件: 145
359Oral prednisolone1件: Prednisolone8件: D00472 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 49, 96, 145
360Oral prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 251
361Oral Prednisone 5mg1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 49
362Oral probiotic----1件: 291
363Oral reduced l-glutathione1件: Glutathione2件: D00014 ,
D00031 		--1件: 299
364Oral roflumilast1件: Roflumilast1件: D05744 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬1件: 299
365Oral SCIO-469 capsule----1件: 46
366Oral selexipag (Uptravi)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
367Oral sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
368Oral sirolimus1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 278
369Oral THC----1件: 13
370Oral treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
371Oral treprostinil (UT-15C) Sustained Release Tablets1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
372Oral Vancomycin1件: Vancomycin2件: D00212 ,
D00926 		--2件: 94, 296
373Oral Viscous Budesonide1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
374Oral Viscous Budesonide (OVB)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
375Orally disintegrating selegiline (Zelapar)1件: Selegiline2件: D00785 ,
D03731 		1件: MAOB 💬14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
376OraPlus----1件: 310
377Orbcel-C1件: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells---2件: 94, 95
378Order of two elements of surgical procedure----1件: 51
379ORE1001----1件: 97
380Orelabrutinib1件: Orelabrutinib1件: D12160 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 13, 61, 63
381Orelabrutinib( higher dose)1件: Orelabrutinib1件: D12160 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬1件: 63
382Orelabrutinib( lower dose)1件: Orelabrutinib1件: D12160 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬1件: 63
383ORENCIA1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬14件: 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271
384Orencia (abatacept)1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
385Orencia (trade name)1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 50
386Orencia 125 mg1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
387ORENCIA 125 mg solution for injection1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
388ORENCIA 125 mg solution for injection in pre-filled syringe1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬3件: 46, 49, 53
389ORENCIA 125 mg, solution injectable en seringue préremplie1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
390ORENCIA 250 mg polvo para concentrado para sol. para perfusión1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
391ORENCIA 250mg powder for concentrate for solution for infusion1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
392Orencia abatacept1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
393ORENCIA Subcutaneous Injection1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
394ORENCIA*IV 2FL 250MG+2SIR1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 46
395Orencia® (Abatacept)1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 95
396ORENCIA® 125 mg solution for injection in pre-filled syringe1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 65
397Orfadin1件: Nitisinone1件: D05177 1件: HPD 💬5件: Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬2件: 6, 241
398Orfadin oral suspension 4mg/ml1件: Nitisinone1件: D05177 1件: HPD 💬5件: Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬1件: 241
399Orfiril Saft----1件: 3
400Originator----2件: 46, 271
401Originator (legacy) drug----4件: 46, 96, 97, 271
402Originator adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
403Originator rituximab - Rituxan ® or MabThera ®1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
404ORILANOLIMAB1件: Orilanolimab1件: D12144 1件: FCGRT 💬-1件: 61
405ORIN1001----1件: 85
406Orkambi1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
407Orkambi 100 mg/125 mg film-coated tablets1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
408Orkambi 200 mg/125 mg film-coated tablets1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
409Orkambi: contains lumacaftor and ivacaftor1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
410Orkambi®1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
411ORL-1B----1件: 255
412ORM-12471----1件: 51
413ORM-12471 30mg----1件: 51
414ORM-127411件: ORM-12741---1件: 51
415ORMONE PARATIROIDEO DA DNA RICOMBINANTE----1件: 235
416Orncia----1件: 46
417Ornithine1件: Ornithine1件: D08302 --2件: 245, 251
418Ornithine alpha ketoglutarate1件: Ornithine1件: D08302 --1件: 245
419OROCAL----1件: 75
420Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg3件: Estradiol,
Ethinylestradiol,
Norgestimate		10件: D00105 ,
D00554 ,
D01413 ,
D01617 ,
D01953 ,
D04061 ,
D04063 ,
D04064 ,
D04065 ,
D05209 		3件: ESR1,
ESR2,
PGR 💬		12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 299
421Ortho-novum1件: Mestranol1件: D00575 2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬2件: 46, 49
422Ortho-Novum 7771件: Mestranol1件: D00575 2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 49
423Ortho-Novum® 1/351件: Mestranol1件: D00575 2件: ESR1,
ESR2 💬		10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 46
424Orthopedic evaluation----1件: 78
425ORY2001----1件: 13
426OS440----1件: 13
427OSCN-----1件: 299
428OSE-127----2件: 53, 97
429Oseltamivir1件: Oseltamivir2件: D00900 ,
D08306 		--2件: 97, 299
430OSILODROSTAT1件: Osilodrostat1件: D11061 1件: CYP11B2 💬3件: Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 75
431Osilodrostat 10mg1件: Osilodrostat1件: D11061 1件: CYP11B2 💬3件: Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 75
432Osilodrostat 1mg1件: Osilodrostat1件: D11061 1件: CYP11B2 💬3件: Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 75
433Osilodrostat 20mg1件: Osilodrostat1件: D11061 1件: CYP11B2 💬3件: Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 75
434Osilodrostat 5mg1件: Osilodrostat1件: D11061 1件: CYP11B2 💬3件: Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 75
435Osmohale----1件: 299
436OSOME----1件: 19
437Ossein hydroxyapatite----1件: 75
438OSSIDO DI AZOTO----1件: 294
439Ossido Nitrico----1件: 86
440OSSITOCINA----1件: 193
441Ossium vBM-MSC----1件: 96
442OST-122----1件: 97
443Osteoblast biology study----1件: 238
444Osteomalacia----1件: 238
445Osteopetrosis Haploidentical Only Preparative Regimen----5件: 19, 20, 125, 234, 326
446Osteopetrosis Only Preparative Regimen----5件: 19, 20, 125, 234, 326
447OSTEOPOR----1件: 75
448OSU 6162 similar to (-)-OSU 6162----1件: 6
449OSU6162 similar to (-)-OSU 6162----2件: 6, 8
450OT----1件: 193
451Otelixizumab1件: Otelixizumab1件: D08959 3件: CD3D,
CD3E,
CD3G 💬		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 46
452Otezla1件: Apremilast1件: D08860 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬3件: 56, 107, 162
453OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG1件: Apremilast1件: D08860 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬2件: 56, 107
454OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE1件: Apremilast1件: D08860 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬1件: 107
455Other analgesics and antipyretics----1件: 13
456Other antiepileptics----1件: 140
457Other Biologic Therapies----2件: 96, 97
458Other biological agent----2件: 46, 96
459Other Biologics----1件: 46
460Other COX-2 inhibitor----1件: 271
461Other Cox-2 inhibitors----1件: 271
462Other Crystalloid----1件: 296
463Other disease-modifying therapy----1件: 13
464Other DMARDs----1件: 46
465Other H1 antagonist----1件: 13
466Other hematological Agents----1件: 65
467Other intervention(s)----1件: 70
468OTHER NERVOUS SYSTEM DRUGS----2件: 6, 13
469Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac1件: Etodolac1件: D00315 1件: PTGS2 💬22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46
470Other Non-selective NSAIDs----1件: 271
471Other non-sponsor pancreatic enzyme replacement therapy----1件: 299
472Other Parkinson's Disease treatments----1件: 6
473Other respiratory system products----1件: 299
474OTHER SOURCES----1件: 228
475Other vasodilator----1件: 51
476Other:----2件: 2, 65
477Other: 0 mg----1件: 97
478Other: 0.02% Fm, SH, tBCL----1件: 53
479Other: 0.9% sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 65
480Other: 0.9ml sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 271
481Other: 1 Food Elimination Diet----1件: 98
482Other: 1 Food Elimination Diet Therapy----1件: 98
483Other: 100% pomegranate juice1件: Pomegranate---2件: 96, 97
484Other: 13C6 Leucine1件: Leucine1件: D00030 --3件: 5, 7, 127
485Other: 18F-FDG1件: Fludeoxyglucose (18F)---2件: 46, 84
486Other: 18F-FDG PET/CT1件: Fludeoxyglucose (18F)---1件: 41
487Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT1件: Fludeoxyglucose (18F)---1件: 84
488Other: 18F-GE-1801件: Flutriciclamide F-18---1件: 46
489Other: 2h standardized aerobic exercise----1件: 78
490Other: 3-days water-fasting1件: Water1件: D00001 --1件: 67
491Other: 31-Phosphorus RMN Spectroscopy1件: Phosphorus---1件: 8
492Other: 4 Food Elimination Diet----1件: 98
493Other: 4 Food Elimination Diet (post 1FED failure)----1件: 98
494Other: 5-ASA Withdrawal1件: Mesalazine1件: D00377 --1件: 96
495Other: 6 Food Elimination Diet (after 1FED failure)----1件: 98
496Other: 6 Food Elimination Diet Therapy----1件: 98
497Other: 60% Oxygen1件: Oxygen1件: D00003 --1件: 85
498Other: [11C]-Methionine PET/MRI1件: Methionine2件: D00019 ,
D04983 		--1件: 75
499Other: [11C]donepezil PET1件: Donepezil2件: D00670 ,
D07869 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
500Other: A-STEP----1件: 299
501Other: A-STEP (New Protocol)----1件: 299
502Other: Abdominal compression----1件: 17
503Other: Absorptive clearance scan----1件: 299
504Other: Acute response to high-impact exercise----1件: 96
505Other: Ad libitum water intake1件: Water1件: D00001 --1件: 67
506Other: Adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
507Other: Adalimumab treatment1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 151
508Other: Additional Therapies----1件: 97
509Other: Air - oxygen1件: Oxygen1件: D00003 --1件: 299
510Other: Aminoacid, alanine-infusion1件: Alanine1件: D00012 --1件: 251
511Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised----1件: 2
512Other: Antigen (wheat base soy sauce) spray1件: Wheat1件: D06902 --1件: 98
513Other: anxiety----1件: 13
514Other: Assessment of medication compliance----1件: 98
515Other: At-home natalizumab treated MS patient1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
516Other: Autogenic drainage----1件: 299
517Other: Autologous Platelet rich plasma----1件: 35
518Other: autologous serum and rebamipide 2%1件: Rebamipide1件: D01121 --1件: 53
519Other: Avise PG - Diagnostic test----1件: 46
520Other: Balance1件: Isoxaflutole---3件: 6, 13, 299
521Other: Balance exercise1件: Isoxaflutole---1件: 6
522Other: Balance exercise program using exoskeleton device1件: Isoxaflutole---1件: 13
523Other: Balance exercises1件: Isoxaflutole---1件: 13
524Other: Balance Trainer Balance Exercises1件: Isoxaflutole---1件: 13
525Other: Balance Training1件: Isoxaflutole---2件: 6, 13
526Other: Baseline serum vitamin D level at or above 50 nmol/l1件: Vitamin D---1件: 46
527Other: Baseline serum vitamin D level below 50 nmol/l1件: Vitamin D---1件: 46
528Other: beetroot juice extract----1件: 113
529Other: Berg Balance Scale1件: Isoxaflutole---2件: 6, 13
530Other: Best Medical Treatment----1件: 6
531Other: Best Practice----1件: 60
532Other: Biological samples----1件: 206
533Other: Biopsy----1件: 51
534Other: Blood analysis for frataxin's level measurement----1件: 18
535Other: Blood collection for measurement of eculizumab peak concentrations1件: Eculizumab1件: D03940 1件: C5 💬10件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 62
536Other: Blood drawing only Group C----1件: 49
537Other: Blood draws----3件: 49, 51, 85
538Other: Blood glucose results1件: Dextrose, unspecified form---1件: 299
539Other: blood sample----1件: 299
540Other: Blood sample and cotton skin swabs1件: Cotton---1件: 162
541Other: Blood samples----1件: 93
542Other: Blood sampling for Laboratory Developed Test (LDT) analysis----1件: 65
543Other: Blood test----2件: 83, 96
544Other: Blood-flow restricted training----1件: 15
545Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.----1件: 230
546Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.----1件: 230
547Other: Bone Marrow aspiration----1件: 2
548Other: Bone Marrow Cell Transplantation----1件: 274
549Other: Brain MRI (magnetic resonance imaging)----1件: 17
550Other: Brief Pain Inventory questionnaire----1件: 19
551Other: Bronchoalveolar samples----1件: 51
552Other: BSC----1件: 85
553Other: Caffeine1件: Caffeine2件: D00528 ,
D01453 		11件: ADORA1,
ADORA2A,
PDE1B,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE5A 💬		22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
554Other: Calcium stable isotope1件: Calcium---1件: 186
555Other: Carbon monoxide-bubbled mediums2件: Activated charcoal,
Carbon monoxide		1件: D09706 --1件: 298
556Other: carboxy methyl cellulose2件: Methylcellulose,
Microcrystalline cellulose		2件: D00093 ,
D04996 		--1件: 53
557Other: Cardiopulmonary evaluation----1件: 13
558Other: Cawthorne Cooksey exercises----1件: 13
559Other: CD LFD----1件: 96
560Other: CD-TREAT diet----1件: 96
561Other: Challenge agent: capsaicin1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 19
562Other: Classic, progressive endurance training----1件: 13
563Other: Clinical data collection----3件: 49, 51, 85
564Other: clinical observation----1件: 205
565Other: CoA-Z----1件: 120
566Other: Coaching Sessions----1件: 49
567Other: CoDuSe balance training and step square exercises1件: Isoxaflutole---1件: 13
568Other: Coffee1件: Arabica coffee bean---1件: 96
569Other: Cognitive training----1件: 206
570Other: Colchicine Cessation1件: Colchicine1件: D00570 9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 266
571Other: collection of CSF, blood, urine, saliva----1件: 6
572Other: Communicative Effectiveness Survey----1件: 2
573Other: Comparator: CPET cycle ergometer (Gold Standard)1件: Gold---1件: 299
574Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease1件: Isoxaflutole---1件: 6
575Other: Concomitant Medication----1件: 49
576Other: Continuation of dornase alfa (dnase)1件: Dornase alfa1件: D03896 --1件: 299
577Other: Continuation of hypertonic saline (HS)----1件: 299
578Other: continue their usual therapy----1件: 66
579Other: Control----9件: 6, 19, 67, 70, 75, 85, 97, 162, 193
580Other: Control Diet----1件: 96
581Other: Control group----1件: 2
582Other: Control group(Normal saline)----1件: 97
583Other: Control wound treatment----1件: 36
584Other: Controlled environment tests (series of tasks of everyday life)----1件: 6
585Other: Controls Primary Cervical Dystonia (Trihexyphenidyl)1件: Trihexyphenidyl2件: D00787 ,
D08638 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
586Other: conventional balance training1件: Isoxaflutole---1件: 13
587Other: Conventional drugs----1件: 97
588Other: Conventional PCA mode----1件: 70
589Other: Conventional physiotherapy----1件: 6
590Other: Core stability----1件: 13
591Other: corn starch1件: Starch, corn1件: D05297 --1件: 49
592Other: corticotropin releasing hormone (CRH)1件: Corticotropin1件: D00146 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 78
593Other: Cough monitor1件: Methamidophos---1件: 85
594Other: Covid-19 vaccine----1件: 13
595Other: Crohn's disease exclusion diet (CDED)----1件: 96
596Other: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)----1件: 96
597Other: Crohns Disease Exclusion Diet----1件: 96
598Other: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation----1件: 65
599Other: Cultured Thymus Tissue Implantation with Parathyroid Transplantation----1件: 65
600Other: current treatment----1件: 46
601Other: cyclosporin A1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
602Other: Cysteamine bitartrate1件: Cysteamine2件: D03634 ,
D03635 		--1件: 19
603Other: D-xylose1件: Xylose1件: D06346 --1件: 98
604Other: D5W----1件: 222
605Other: Data Capture1件: Bifenthrin---1件: 6
606Other: De-implementation of Inhaled Nitric Oxide (iNO) use1件: Nitric Oxide1件: D00074 --1件: 294
607Other: Dead Sea Solar and Water Treatment1件: Water1件: D00001 --1件: 46
608Other: Determination of calcium intake by a dietician interview1件: Calcium---2件: 13, 46
609Other: dextrose water 5%2件: Dextrose, unspecified form,
Water		1件: D00001 --1件: 56
610Other: diagnostic laboratory biomarker analysis----1件: 74
611Other: Diagnostics for glucose tolerance with 3 different methods.1件: Dextrose, unspecified form---1件: 299
612Other: Diary completion----1件: 6
613Other: Diet----1件: 240
614Other: Diet treatment----1件: 240
615Other: Diet-CD----1件: 96
616Other: dietary intervention with no-carrageenan diet----1件: 97
617Other: Dietary recommendations----1件: 51
618Other: Digestible Maltodextrin1件: Maltodextrin1件: D02329 --1件: 96
619Other: Discontinuation of dornase alfa (dnase)1件: Dornase alfa1件: D03896 --1件: 299
620Other: Discontinuation of hypertonic saline (HS)----1件: 299
621Other: DMT withdrawal----1件: 13
622Other: dobutamine1件: Dobutamine4件: D00632 ,
D03879 ,
D03880 ,
D03881 		1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 215
623Other: Donor derived G-CSF mobilized PBC1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 60
624Other: Donor Lymphocyte Infusion----1件: 65
625Other: Dosage of Delta-aminolevulinic acid and Porphobilinogen2件: Aminolevulinic acid,
Porphobilinogen		2件: D02908 ,
D07567 		--1件: 254
626Other: Dose reduction to 2mg/L----1件: 46
627Other: Dose reduction to 5mg/L----1件: 46
628Other: Dried blood spot test for MPS----1件: 19
629Other: Drug free----1件: 49
630Other: Dual Task Performance----1件: 13
631Other: Dummy Tripterygium wilfordii Hook F (TwHF)1件: Tripterygium wilfordii whole---1件: 46
632Other: Dynamic Balance Training1件: Isoxaflutole---1件: 13
633Other: Dynamic balance walking training1件: Isoxaflutole---1件: 13
634Other: Dystrophin levels----1件: 113
635Other: DYT 1 Dystonia----1件: 6
636Other: DYT 1 Dystonia (Healthy Control)----1件: 6
637Other: e-Monitoring----1件: 97
638Other: Eating Assessment Tool 10----1件: 2
639Other: Eating Assessment Tool-10----1件: 2
640Other: Echocardiogram----1件: 113
641Other: Eculizumab1件: Eculizumab1件: D03940 1件: C5 💬10件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 109
642Other: EEnG Questionnaire----1件: 291
643Other: EIT----1件: 228
644Other: Electroencephalogram (EEG) awake andextended overnight----1件: 19
645Other: Elektro-Entero-Graphy procedure----1件: 291
646Other: Elimination diet----1件: 98
647Other: Empiric use of Calcium Carbonate and Calcitriol4件: Calcitriol,
Calcium,
Calcium carbonate,
Carbonate ion		3件: D00129 ,
D00932 ,
D10802 		1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 235
648Other: Endurance----1件: 6
649Other: enteral nutrition----1件: 96
650Other: Epiduroscopy----1件: 70
651Other: Epistaxis charts----1件: 227
652Other: EUS procedure----1件: 298
653Other: Evaluation by Investigator----1件: 6
654Other: Evaluation of degree chronic fatigue.----1件: 13
655Other: Event-related evoked potential using electroencephalography (EEG).----1件: 6
656Other: Exclusion Diet----1件: 96
657Other: Exclusive enteral nutrition----1件: 96
658Other: Exclusive Enteral Nutrition (EEN)----1件: 96
659Other: Exercise capacity----1件: 299
660Other: Exercise echocardiography----1件: 58
661Other: Exercise followed cold water immersion1件: Water1件: D00001 --1件: 46
662Other: Exercise intervention----2件: 13, 18
663Other: Exposure to methylprednisolone during pregnancy1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 13
664Other: Extracorporeal Photopheresis (ECP) with Methoxsalen1件: Methoxsalen1件: D00139 --1件: 51
665Other: Faecal bacterial transplantation----1件: 97
666Other: Fast Mimicking Diet----1件: 97
667Other: fatigue----1件: 13
668Other: Fear of falling----1件: 13
669Other: fingolimod1件: Fingolimod1件: D10001 1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
670Other: Fitbit Activity Monitor1件: Methamidophos---1件: 49
671Other: flow cytometry----3件: 28, 51, 60
672Other: Fluid Restriction----1件: 72
673Other: Fluorescein angiography1件: Fluorescein2件: D01261 ,
D02024 		--1件: 19
674Other: fog----1件: 6
675Other: Follow-up study of the untreated cohort----1件: 193
676Other: Food Diary----1件: 65
677Other: Four Square Step Test----2件: 6, 13
678Other: Fractional Exhaled NO (FENO)----1件: 96
679Other: Fresh Frozen Plasma----1件: 14
680Other: Fruit juice----1件: 299
681Other: Functional involvement of identified epigenetic alterations----1件: 102
682Other: Functional mobility----2件: 6, 13
683Other: Functional Oral Intake Scale----1件: 2
684Other: Functional Reach Test----2件: 6, 13
685Other: Gadobutrol1件: Gadobutrol1件: D07420 --1件: 46
686Other: Gait and balance group training1件: Isoxaflutole---1件: 6
687Other: General and Neurological examination----1件: 19
688Other: general population----2件: 46, 271
689Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy----1件: 102
690Other: Genetic data/DNA/RNA----3件: 49, 51, 85
691Other: GH pause----1件: 78
692Other: GHRH plus arginine test2件: Arginine,
Somatorelin		2件: D02982 ,
D08523 		1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
693Other: GHRH+Arg, GHRH+Arg, ITT1件: Somatorelin1件: D08523 1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
694Other: Glucose1件: Dextrose, unspecified form---1件: 254
695Other: Glucose -potentiated arginine (GPA) stimulation tests2件: Arginine,
Dextrose, unspecified form		1件: D02982 --1件: 299
696Other: Glucose profile for 2 weeks1件: Dextrose, unspecified form---1件: 299
697Other: glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT1件: Dextrose, unspecified form---1件: 299
698Other: Glycerine gel1件: Glycerin1件: D00028 --1件: 265
699Other: Gold Standard Questionnaire1件: Gold---1件: 291
700Other: Green tea (Camellia sinensis)1件: Green tea leaf1件: D06903 --1件: 96
701Other: Groningen Anti-Inflammatory Diet (GrAID)----1件: 96
702Other: Group 2 (DMARDS treated group)----1件: 46
703Other: Group B SLE one blood donation----1件: 49
704Other: Group balance training1件: Isoxaflutole---1件: 13
705Other: Group Exercise: community setting----1件: 70
706Other: Growth hormone1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
707Other: GSK2586184 single dose taken with food----1件: 49
708Other: GSK2586184 single dose taken without food----1件: 49
709Other: Haematopoietic Stem Cell Transplantation (HSCT)----1件: 65
710Other: Hand training----1件: 46
711Other: Harkány medicinal water1件: Water1件: D00001 --1件: 46
712Other: healthy controls----1件: 63
713Other: Healthy volunteers----1件: 46
714Other: hemicellulose crystalline----1件: 6
715Other: Hepatic elastography----1件: 299
716Other: High energy / protein diet.----1件: 96
717Other: High Glycemic Index Meal----1件: 299
718Other: High intensity exercise and balance training1件: Isoxaflutole---1件: 6
719Other: high performance liquid chromatography----1件: 96
720Other: High resolution peripheral quantitative computed tomography (HRpQCT)----1件: 172
721Other: High Water Intake1件: Water1件: D00001 --1件: 67
722Other: High-impact exercise intervention----1件: 96
723Other: High-intensity training in shallow and deep water1件: Water1件: D00001 --1件: 6
724Other: Histamine1件: Histamine1件: D08040 4件: HRH1,
HRH2,
HRH3,
HRH4 💬		4件: Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 13
725Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations----1件: 102
726Other: Historical control----1件: 2
727Other: Hoehn and Yahr Scale----1件: 6
728Other: Home functional balance physiotherapy1件: Isoxaflutole---1件: 6
729Other: Honey1件: Honey1件: D06776 --1件: 98
730Other: Human Milk Derived Fortifier1件: Cow milk---1件: 210
731Other: Human umbilical cord-derived MSCs and cyclosporin A1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
732Other: Human/Bovine Milk1件: Cow milk---1件: 210
733Other: Hydrocortisone1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 75
734Other: Hydrogen peroxide2件: Hydrogen,
Hydrogen peroxide		1件: D00008 --1件: 13
735Other: Hydroxychloroquine/Chloroquine2件: Chloroquine,
Hydroxychloroquine		4件: D02125 ,
D02366 ,
D03469 ,
D08050 		--1件: 46
736Other: Hyperbaric oxygen1件: Oxygen1件: D00003 --1件: 96
737Other: Hyperbaric Oxygen Therapy1件: Oxygen1件: D00003 --2件: 97, 226
738Other: Hyperpolarized Xenon MRI1件: Xenon2件: D01901 ,
D06339 		--1件: 299
739Other: Hypoglycemic Clamp----1件: 299
740Other: Hypothyroidism QOL questionnaire----1件: 80
741Other: Ibuprofen and Isosorbide Dinitrate combination2件: Ibuprofen,
Isosorbide dinitrate		5件: D00126 ,
D00516 ,
D01122 ,
D04490 ,
D06606 		2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 113
742Other: Iloprost (Ventavis inhaled, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
743Other: Imaging----1件: 13
744Other: Imitation Surgical Procedure (ISP)----1件: 6
745Other: immunologic technique----1件: 49
746Other: Impact of biotherapy on postoperative morbidity in ulcerative colitis----1件: 97
747Other: Impact Peptide 1.5----1件: 299
748Other: inactive drug----1件: 226
749Other: Incontinence Severity----1件: 13
750Other: Individualized exercises: clinical setting----1件: 70
751Other: Induced hypotonic hyponatremia - SIAD model----1件: 72
752Other: infliximab (IFX) infusion1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
753Other: Inhalable Hypertonic saline 7%----1件: 299
754Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%1件: Hyaluronic acid1件: D08043 --1件: 299
755Other: Inhaled Hyperpolarized Xenon-1291件: Xenon2件: D01901 ,
D06339 		--1件: 228
756Other: Intensify treatment with the existing drug----2件: 96, 97
757Other: intensive supportive care----1件: 66
758Other: Intrathecal saline injection----1件: 13
759Other: ISA 51----1件: 50
760Other: ISA 51 VG----1件: 49
761Other: ITT, ITT, GHRH+Arg.1件: Somatorelin1件: D08523 1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
762Other: IV saline infusion----1件: 96
763Other: IV steroids combination alone----1件: 41
764Other: IVIg1件: Human immunoglobulin G---1件: 35
765Other: Joint Mobilizations (spine, sacroiliac, hip)----1件: 70
766Other: Kesimpta1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
767Other: Ketogenic Diet----2件: 19, 67
768Other: Lab Work----1件: 46
769Other: Laboratory Biomarker Analysis----21件: 11, 13, 14, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 205, 232, 283, 284, 285, 298, 331
770Other: Language Intervention----1件: 206
771Other: Lengthening adalimumab dosing interval1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
772Other: Leukapheresis- Collection of stem cells----1件: 96
773Other: levothyroxine1件: Levothyroxine2件: D01010 ,
D08125 		2件: THRA,
THRB 💬		2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬1件: 78
774Other: Liberation therapy----1件: 13
775Other: Liquid Meal Test (Carbohydrate-rich)----1件: 299
776Other: Liquid Meal Test (Fat-rich)----1件: 299
777Other: Liquid Meal Test (Mixed)----1件: 299
778Other: Liver Evaluation----1件: 240
779Other: Liver questionnaire----1件: 231
780Other: Losartan1件: Losartan2件: D00357 ,
D08146 		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 46
781Other: Low Blood Pressure Control----1件: 67
782Other: Low dose (1 mcg) ACTH stimulation test1件: Corticotropin1件: D00146 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 193
783Other: Low Glycemic Index Meal----1件: 299
784Other: Low n-6 PUFA Diet----1件: 96
785Other: Low-intensity exercise therapy----1件: 298
786Other: Lower Limb Strength----1件: 6
787Other: Magnetic Resonance Imaging (MRI)----1件: 113
788Other: Mangafodipir trisodium1件: Mangafodipir1件: D08262 --1件: 58
789Other: Meal Challenge----1件: 240
790Other: measure of endothelial function----1件: 299
791Other: Measurement of drug (Adalimumab/Infliximab)2件: Adalimumab,
Infliximab		2件: D02597 ,
D02598 		1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 96, 97
792Other: Medical air2件: Medical air,
Oxygen		1件: D00003 --1件: 85
793Other: medical chart review----1件: 60
794Other: Medical History Questionnaires----1件: 65
795Other: Medication Compliance Phone Call----1件: 98
796Other: Mesalazine1件: Mesalazine1件: D00377 --1件: 97
797Other: Metabolic Exercise Testing using stationary bicycle----1件: 113
798Other: Metformin1件: Metformin2件: D00944 ,
D04966 		2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 46
799Other: Methacholine Challenge Test1件: Methacholine---1件: 96
800Other: Methotrexate therapy1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
801Other: MIBG label with I123 or I124----1件: 6
802Other: Microindentation----1件: 172
803Other: mitoxantrone - immunomodulator1件: Mitoxantrone2件: D02166 ,
D08224 		2件: TOP2A,
TOP2B 💬		1件: Platinum drug resistance 💬1件: 13
804Other: Mixed meal test evaluation test arm----1件: 299
805Other: Mixed Meal Tolerance Test----1件: 299
806Other: Mobile platform exercise----1件: 6
807Other: Mock injection----1件: 90
808Other: modified Atkins diet----1件: 145
809Other: Modified Mixed Meal Tolerance Test----1件: 65
810Other: Modified Oral Glucose Tolerance Test1件: Dextrose, unspecified form---1件: 65
811Other: Modified paleolithic diet----1件: 13
812Other: Monthly assessments of functional motor abilities by a trained therapist----1件: 3
813Other: Motor Assessments before taking regular PD treatment----1件: 6
814Other: Motor Assessments on regular PD treatment----1件: 6
815Other: MP+DDCI----1件: 6
816Other: MP-Equivalent----1件: 6
817Other: MP-Low----1件: 6
818Other: MPS I----1件: 19
819Other: MRI----3件: 6, 127, 206
820Other: MSCs----1件: 13
821Other: Multidisciplinary intensive rehabilitation treatment----1件: 6
822Other: Muscle oxygenation----1件: 299
823Other: Music----1件: 6
824Other: myBETAapp----1件: 13
825Other: N-thymidine1件: Thymidine---1件: 215
826Other: Natalizumab1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
827Other: Natalizumab discontinuation1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
828Other: natural herbs of coconut, aloe vera, and pepperint2件: Aloe vera leaf,
Coconut		---1件: 53
829Other: NBT-NM108 (0 g/day)----1件: 13
830Other: Neupro 4 mg / 24 Hr. Transdermal Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
831Other: Neurology exam----1件: 19
832Other: Neuromuscular evaluation----1件: 13
833Other: Nil per os----1件: 291
834Other: Nintendo Wii Fit Balance exercises1件: Isoxaflutole---1件: 13
835Other: No active treatment----1件: 274
836Other: No anti-inflammatory treatment----1件: 271
837Other: No device----1件: 13
838Other: No doxycycline1件: Doxycycline5件: D00307 ,
D02129 ,
D03903 ,
D03904 ,
D07876 		--1件: 299
839Other: No enzyme therapy----1件: 298
840Other: NO intervention----4件: 13, 70, 96, 97
841Other: No Intervention: Standard of Care----1件: 85
842Other: No IT treatment----1件: 19
843Other: No MSDMDs therapy (control)----1件: 13
844Other: No pancreatic enzyme replacement therapy----1件: 299
845Other: No Plasma Exchange----2件: 43, 44
846Other: No treatment----2件: 53, 274
847Other: No Treatment Arm----1件: 13
848Other: No treatment given----1件: 78
849Other: Non Impact Aerobics----1件: 13
850Other: Non-hormonal period----1件: 299
851Other: Non-Motor Symptoms----1件: 6
852Other: Noninvasive actigraphy monitor1件: Methamidophos---1件: 86
853Other: Nordic walking (only osteoporosis group)----1件: 6
854Other: Normal (control) diet----1件: 240
855Other: normal diet----1件: 96
856Other: normal saline----4件: 13, 222, 226, 280
857Other: Normal Saline for injection----1件: 84
858Other: NS----1件: 96
859Other: Numerical rating scale----1件: 46
860Other: Nutrition counseling----1件: 298
861Other: Obese----1件: 75
862Other: Observation----1件: 265
863Other: Observation of Ocrelizumab as Treatment in RRMS Patients1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
864Other: Observation Only----1件: 331
865Other: Observational----1件: 90
866Other: Observational cohort----1件: 6
867Other: Observational Control----1件: 13
868Other: Ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
869Other: Ofatumumab1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
870Other: OGTT----1件: 299
871Other: On-demand treatment----1件: 299
872Other: One-leg Stance Test----1件: 13
873Other: Ophthalmologic examinations----1件: 299
874Other: Optimized Supportive Care----1件: 66
875Other: Optimizing basal infusion (B.I)----1件: 70
876Other: Optional Blood-Oxygen-level Dependent functionalMRI1件: Oxygen1件: D00003 --1件: 6
877Other: Oral Glucose tolerance test1件: Dextrose, unspecified form---3件: 160, 195, 299
878Other: Oral Glucose Tolerance Test (OGTT) assessment arm1件: Dextrose, unspecified form---1件: 299
879Other: Oral Nitric Oxide testing1件: Nitric Oxide1件: D00074 --1件: 98
880Other: Other Biologic Agents----2件: 96, 97
881Other: Other biological samples to biobank (skin, lung and muscle biopsies----3件: 49, 51, 85
882Other: Other intervention(s)----1件: 70
883Other: Other: Disease modifying therapies (DMT)----1件: 13
884Other: Other: Symptomatic treatment of ALS----1件: 2
885Other: Outpatient rheumatology department----1件: 46
886Other: Overnight metyrapone test1件: Metyrapone2件: D00410 ,
D05019 		1件: CYP11B1 💬4件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 193
887Other: Oxygen1件: Oxygen1件: D00003 --1件: 85
888Other: Oxygen (2Liter/min)1件: Oxygen1件: D00003 --1件: 85
889Other: Oxygen (4Liter/min)1件: Oxygen1件: D00003 --1件: 85
890Other: Oxygen - Air1件: Oxygen1件: D00003 --1件: 299
891Other: Oxygen Supplementation1件: Oxygen1件: D00003 --1件: 86
892Other: ozone therapy1件: Ozone---1件: 51
893Other: Packing----1件: 227
894Other: pain----1件: 13
895Other: Palliative Care----5件: 19, 65, 120, 160, 326
896Other: Parkinson mPower mobile application----1件: 6
897Other: Parts A/B: Sham Control----1件: 19
898Other: Passive : lecture series----1件: 13
899Other: PBO----1件: 162
900Other: PCDAI----1件: 96
901Other: PD exercise intervention----1件: 6
902Other: PD vitamin + exercise----1件: 6
903Other: PEAK----1件: 13
904Other: Peanut Butter1件: Peanut---1件: 13
905Other: Pentadecanoic acid (PA) and Triheptadecanoin (THA)----1件: 299
906Other: PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)2件: Aminosalicylic acid,
Mesalazine		2件: D00162 ,
D00377 		--1件: 97
907Other: Periodized exercise training----1件: 13
908Other: Peripheral Blood Stem Cells----2件: 60, 62
909Other: Pharmacogenomic Study----1件: 26
910Other: Pharmacokinetic analysis----1件: 49
911Other: Pharmacological Study----7件: 28, 34, 62, 74, 89, 232, 331
912Other: Phenylalanine (Phe)-restricted diet1件: Phenylalanine1件: D00021 --1件: 240
913Other: Physalis angulata ethanol extract1件: Ethanol4件: D00068 ,
D02798 ,
D04855 ,
D06542 		--1件: 51
914Other: Physical Function Performance Test----1件: 6
915Other: Physical Therapy----2件: 6, 70
916Other: Pittsburgh Compound B [11C]-PIB1件: Pittsburgh Compound B---1件: 6
917Other: Plant-based diet----1件: 46
918Other: plasticity-based computerized cognitive remediation program----1件: 13
919Other: PNF----1件: 13
920Other: Position Sense----1件: 13
921Other: Postoperative nausea and vomiting at 24 hour----1件: 235
922Other: Postoperative nausea and vomiting at 6 hour----1件: 235
923Other: Postoperative pain at 24 hour----1件: 235
924Other: Postoperative pain at 6 hour----1件: 235
925Other: Postoperative sore throat and hoarseness at 24 hour----1件: 235
926Other: Postoperative sore throat and hoarseness at 6 hour----1件: 235
927Other: Potable water1件: Water1件: D00001 --1件: 19
928Other: prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
929Other: pretreatment antibiotics----1件: 97
930Other: Progressive exercise----1件: 13
931Other: propensity score----1件: 13
932Other: Prospective observational registry----1件: 3
933Other: PSP----1件: 13
934Other: PTH based Calcium Carbonate and Calcitriol repletion4件: Calcitriol,
Calcium,
Calcium carbonate,
Carbonate ion		3件: D00129 ,
D00932 ,
D10802 		1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 235
935Other: Pulmonary Function Testing (PFT)----1件: 113
936Other: Pulmonary rehabilitation program----1件: 85
937Other: QALCIMUM questionnaire----2件: 13, 46
938Other: Quality of life assessment----1件: 122
939Other: Quality of Life questionnaire----1件: 19
940Other: Quality-of-Life Assessment----9件: 34, 36, 51, 62, 65, 96, 283, 286, 298
941Other: quercetin1件: Quercetin---1件: 299
942Other: Questionnaire Administration----4件: 16, 34, 51, 298
943Other: Questionnaires----5件: 6, 13, 41, 93, 96
944Other: Reaction Time and Postural Control----1件: 299
945Other: Real-time data capture app1件: Bifenthrin---1件: 46
946Other: Recommendation with regard to nutrition----1件: 6
947Other: Reduction group 1----1件: 46
948Other: Reduction group 2----1件: 46
949Other: Refered to general practice----1件: 46
950Other: Resistance Exercise Program----1件: 46
951Other: Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.1件: Melatonin1件: D08170 2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 149
952Other: Rheumatoid Arthritis Impact of Disease questionnaire----1件: 46
953Other: Rhythmic Auditory Stimulation (RAS)----2件: 6, 13
954Other: Rhythmic Balance-Movement Training (rBMT)1件: Isoxaflutole---1件: 6
955Other: RMST----1件: 256
956Other: Rosemary essential oil1件: Rosemary---1件: 51
957Other: Rotigotine1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
958Other: Routine----1件: 240
959Other: routine management----1件: 291
960Other: routine therapy----1件: 299
961Other: RP% Measurement by FCM as a Diagnostic Test for ITP----1件: 63
962Other: Salbutamol nebulisation and with CPAP1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 228
963Other: Saline----8件: 2, 6, 46, 97, 98, 256, 274, 301
964Other: Saline as a nasal spray----1件: 226
965Other: Saline solution----1件: 67
966Other: Saline solution.----1件: 67
967Other: Screening to prevent falls----1件: 6
968Other: secukinumab1件: Secukinumab1件: D09967 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
969Other: Serum calcium concentrations results1件: Calcium---1件: 235
970Other: serum levels of angiogenin, bFGF, VEGF1件: Basic Fibroblast Growth Factor---1件: 56
971Other: Sham----1件: 301
972Other: Sham (no implant)----1件: 90
973Other: Sham abdominal compression----1件: 17
974Other: Sham Comparator----1件: 299
975Other: Sham group----1件: 6
976Other: Sham procedure----1件: 90
977Other: Sham Surgery----1件: 6
978Other: Sham-procedure----2件: 90, 303
979Other: Sham-procedure (dose cohort 1&2 only)----2件: 90, 303
980Other: Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 46
981Other: Siponimod1件: Siponimod1件: D11460 2件: S1PR1,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
982Other: SLE treatment----1件: 49
983Other: Smartphone Application----1件: 49
984Other: Smartphone-based balance exercises1件: Isoxaflutole---1件: 6
985Other: sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 51
986Other: Specific SL-therapy----1件: 6
987Other: specifically design 6 month resistance training program----1件: 13
988Other: Specimen Collection----1件: 215
989Other: Spinning grp----1件: 13
990Other: Sputum Sample----1件: 299
991Other: Squat-to-stand maneuver----1件: 58
992Other: Standard----1件: 67
993Other: Standard Blood Pressure Control----1件: 67
994Other: Standard care----1件: 227
995Other: standard immune suppression, oral----1件: 228
996Other: Standard nutrition----1件: 96
997Other: standard of care----7件: 13, 49, 64, 85, 96, 245, 246
998Other: Standard of care (SOC)----1件: 62
999Other: Standard of Care Sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 90, 301
1000Other: Standard steroid treatment----1件: 113
1001Other: Standard therapy----1件: 49
1002Other: Standard Treatment----1件: 227
1003Other: Standard treatment according to the Clinical protocols----3件: 49, 51, 235
1004Other: Standard-of-care----1件: 86
1005Other: Standardized meals----1件: 86
1006Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS----1件: 6
1007Other: Static Balance Test1件: Isoxaflutole---1件: 13
1008Other: Stem Cell Transplant----1件: 96
1009Other: Sterile Normal Saline (0.9% NaCl)----1件: 231
1010Other: sterile saline----1件: 46
1011Other: Stool Sample----2件: 6, 299
1012Other: Strength training----1件: 13
1013Other: Strength training in shallow water and dry land1件: Water1件: D00001 --1件: 6
1014Other: Subacute hypoxic exposures----1件: 86
1015Other: Subconjunctival injection of saline----1件: 90
1016Other: Subcortical Stimulation----1件: 6
1017Other: Sugar pill----1件: 90
1018Other: Sulfur Pool & Medicinal Mud----1件: 46
1019Other: Supervised physical therapy----1件: 13
1020Other: Surgery----2件: 74, 96
1021Other: Swallowing Quality of Life Questionnaire----1件: 2
1022Other: Swallowing Related Quality of Life Questionnaire----1件: 2
1023Other: Symptom Survey----1件: 98
1024Other: Symptomatic hypocalcaemia at 24 hour----1件: 235
1025Other: Symptomatic hypocalcaemia at 6 hour----1件: 235
1026Other: Symptomatic therapy----1件: 160
1027Other: t-DCS group----1件: 6
1028Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale1件: Isoxaflutole---1件: 6
1029Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA2件: Indium,
Pentetic acid		1件: D05422 --1件: 299
1030Other: Telerehabilitation Based Functional Balance and Mobility Exercise1件: Isoxaflutole---1件: 6
1031Other: Telerehabilitation Based LSVT BIG Exercise Protocol----1件: 6
1032Other: Test Soda----1件: 299
1033Other: The Center for Neurologic Studies Bulbar Function Scale----1件: 2
1034Other: The Center for Neurologic Study Bulbar Function Scale----1件: 2
1035Other: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire----1件: 149
1036Other: the timed 360° turn test----1件: 6
1037Other: Therapy Education----1件: 97
1038Other: Threonine1件: Threonine1件: D00041 --2件: 96, 97
1039Other: Timed Up an Go Test----1件: 13
1040Other: Timed Up and Go Test----1件: 6
1041Other: Tobacco questionnaire1件: Tobacco leaf---1件: 299
1042Other: Tobramycin time of administration1件: Tobramycin2件: D00063 ,
D02542 		--1件: 299
1043Other: Training groupe----1件: 13
1044Other: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.----1件: 215
1045Other: triangular test----1件: 96
1046Other: Trunk impairment----1件: 13
1047Other: Trunk Impairment Scale----1件: 6
1048Other: Trunk position sense----1件: 13
1049Other: tyramine1件: Tyramine---1件: 6
1050Other: UC-MSCs by peripheral intravenous infusion1件: Human Umbilical Cord Mesenchymal Stem Cells---1件: 96
1051Other: Ulcerative Colitis Diet----1件: 97
1052Other: Ultrasonography assessment----1件: 49
1053Other: Unified Parkinson's Disease Rating Scale----1件: 6
1054Other: Untreated Cohort----1件: 85
1055Other: Untreated contemporaneous cohort----1件: 118
1056Other: Urine Collection----1件: 215
1057Other: Use of a postpartum diary and additional blood draws----1件: 288
1058Other: Use of a postpartum diary and additional blood draws.----1件: 288
1059Other: USPIO MRI - Gadolinium MRI1件: Gadolinium---1件: 13
1060Other: Usual care----3件: 46, 107, 299
1061Other: Usual care arm exercise----1件: 6
1062Other: Usual drug treatment of Parkinson's disease----1件: 6
1063Other: Valsalva----1件: 58
1064Other: Vegan Diet----1件: 46
1065Other: Vegetable Oil----1件: 257
1066Other: Vehicle----1件: 160
1067Other: Vehicle (D5W or saline)----1件: 66
1068Other: Vestibular habituation exercises----1件: 13
1069Other: Vestibular rehabilitation: balance and eye movement exercises1件: Isoxaflutole---1件: 13
1070Other: Virtual reality group----1件: 13
1071Other: Visual Acuity (VA)----2件: 90, 301
1072Other: Vital signs----1件: 19
1073Other: Vitamin K1件: Phylloquinone1件: D00148 --1件: 13
1074Other: Vitamin K Cream1件: Phylloquinone1件: D00148 --1件: 13
1075Other: Voluntary cough test----1件: 6
1076Other: Walk distance test----1件: 58
1077Other: Water1件: Water1件: D00001 --1件: 67
1078Other: Water prescription1件: Water1件: D00001 --1件: 67
1079Other: Wheat flour1件: Wheat1件: D06902 --1件: 266
1080Other: Withdrawal from alpha1 antitrypsin replacement therapy----1件: 231
1081Other: Withdrawal of dalfampridine-ER 10mg1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
1082Other: Xanthan Gum1件: Xanthan gum1件: D06333 --1件: 98
1083OTILIMAB1件: Otilimab1件: D11343 1件: CSF2 💬16件: Acute myeloid leukemia, Amoebiasis, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis, Shigellosis, T cell receptor signaling pathway, TNF signaling pathway, Transcriptional misregulation in cancer 💬2件: 46, 256
1084Otilimab (GSK3196165)1件: Otilimab1件: D11343 1件: CSF2 💬16件: Acute myeloid leukemia, Amoebiasis, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis, Shigellosis, T cell receptor signaling pathway, TNF signaling pathway, Transcriptional misregulation in cancer 💬1件: 46
1085OTL-101----1件: 65
1086OTL-103----1件: 65
1087OTL-103 Dispersion for Infusion----1件: 65
1088OTL-200----1件: 19
1089OTL-200 Dispersion for Infusion----1件: 19
1090OTL38----1件: 46
1091Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4----1件: 11
1092OV101----2件: 201, 206
1093OV101 (gaboxadol)1件: Gaboxadol1件: D04282 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 206
1094OV101 Regimen 1----1件: 201
1095OV101 regimen 2----1件: 201
1096Ova-Treg----1件: 96
1097Ovasave----1件: 96
1098OVASTAT1件: Treosulfan1件: D07253 --2件: 13, 65
1099Ovastat 10001件: Treosulfan1件: D07253 --2件: 13, 65
1100Ovastat 1000 (Treosulfan injection)1件: Treosulfan1件: D07253 --1件: 65
1101Ovastat 1000 mg, powder for solution for infusion1件: Treosulfan1件: D07253 --1件: 65
1102Ovastat 50001件: Treosulfan1件: D07253 --2件: 13, 65
1103Ovastat 5000 (Treosulfan injection)1件: Treosulfan1件: D07253 --1件: 65
1104Ovastat 5000 mg, powder for solution for infusion1件: Treosulfan1件: D07253 --1件: 65
1105Over encapsulated prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 41
1106Over the counter DHA/EPA dietary supplementation----1件: 301
1107Over-encapsulated 150 mg Irbesartan Tablets1件: Irbesartan1件: D00523 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 66
1108Over-encapsulated 75 mg Irbesartan Tablets1件: Irbesartan1件: D00523 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222
1109Over-encapsulated Entacapone Tablets1件: Entacapone1件: D00781 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
1110Over-encapsulated Irbesartan1件: Irbesartan1件: D00523 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 66, 222
1111Over-encapsulated Irbesartan Tablets1件: Irbesartan1件: D00523 1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 66, 222
1112Over-encapsulated Modafinil1件: Modafinil1件: D01832 --1件: 6
1113Overencapsulated Azathioprine (Imuran) 50 mg Tablet1件: Azathioprine2件: D00238 ,
D03033 		--1件: 97
1114Overencapsulated mesalazine tablets1件: Mesalazine1件: D00377 --1件: 97
1115Overencapsulated Prednisolone Tablets1件: Prednisolone8件: D00472 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
1116Ovine Corticotropin-Releasing Hormone (oCRH)2件: Corticorelin,
Corticotropin		2件: D00146 ,
D03905 		3件: CRHR1,
CRHR2,
MC2R 💬		6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75
1117Oxadrop----1件: 96
1118Oxaloacetate----1件: 11
1119Oxaloacetate (OAA)----1件: 6
1120Oxandrolone1件: Oxandrolone1件: D00462 1件: AR 💬4件: Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬2件: 211, 285
1121Oxanest----1件: 70
1122Oxatomide1件: Oxatomide1件: D01773 1件: ALOX5 💬6件: Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis 💬1件: 113
1123Oxatomide (tinset)1件: Oxatomide1件: D01773 1件: ALOX5 💬6件: Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis 💬1件: 113
1124OXB-102----1件: 6
1125Oxcarbazepine1件: Oxcarbazepine1件: D00533 5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 13
1126Oxepa----1件: 2
1127OXERVATE1件: Cenegermin1件: D11028 1件: NGFR 💬8件: Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer 💬1件: 53
1128OXICODONE DC.IT----1件: 46
1129Oxiconazole1件: Oxiconazole2件: D00885 ,
D08313 		--1件: 160
1130Oxiklorin----1件: 46
1131Oxine1件: Oxyquinoline1件: D05321 --1件: 13
1132OXN 10 mg / 5 mg PR----1件: 6
1133OXN 10/5 mg PR----1件: 226
1134OXN 20 mg / 10 mg PR----1件: 6
1135OXN 20/10 mg PR----1件: 226
1136OXN 5 mg/2.5 mg PR----1件: 6
1137OXN 5/2.5 mg PR----1件: 226
1138Oxybate1件: gamma-Hydroxybutyric acid---2件: 6, 149
1139Oxybuprocaine1件: Oxybuprocaine2件: D01768 ,
D08319 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 6
1140Oxybutynin1件: Oxybutynin2件: D00465 ,
D00722 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬3件: 6, 13, 53
1141Oxybutynin and darifenacin2件: Darifenacin,
Oxybutynin		4件: D00465 ,
D00722 ,
D01699 ,
D03654 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
1142Oxybutynin hydrochloride1件: Oxybutynin2件: D00465 ,
D00722 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬2件: 6, 13
1143Oxybutynin, tolterodine, solifenacin3件: Oxybutynin,
Solifenacin,
Tolterodine		6件: D00465 ,
D00646 ,
D00722 ,
D01148 ,
D01269 ,
D08522 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 53
1144OXYCODO----1件: 6
1145Oxycodone1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬7件: 6, 13, 46, 70, 226, 231, 298
1146Oxycodone by patient-controlled analgesia (PCA)1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 46
1147Oxycodone Depot ”Sandoz”, depot tablets1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 298
1148OXYCODONE HYDROCHLORIDE1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬4件: 6, 70, 226, 298
1149Oxycodone naloxone prolonged release tablets2件: Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
1150Oxycodone Orion1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 70
1151Oxycodone/Acetaminophen1件: Acetaminophen1件: D00217 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 231
1152Oxycodone/naloxone prolonged release t3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
1153Oxycodone/Naloxone Prolonged Release tablets2件: Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1154Oxycodone/naloxone prolonged release tablets 10 mg /5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1155Oxycodone/naloxone prolonged release tablets 10/5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
1156Oxycodone/naloxone prolonged release tablets 20 mg /10 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1157Oxycodone/naloxone prolonged release tablets 20/10 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
1158Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1159Oxycodone/naloxone prolonged release tablets 5/2.5 mg3件: Manganese citrate,
Naloxone,
Oxycodone		5件: D01340 ,
D03783 ,
D05312 ,
D05462 ,
D08249 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 226
1160Oxycodonhydrochlorid ”Lannacher”, depot tablets----1件: 298
1161Oxycontin LP 10mg1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1162Oxycontin LP 20mg1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1163Oxycontin LP 5mg1件: Oxycodone3件: D03783 ,
D05312 ,
D05462 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 6
1164Oxygen1件: Oxygen1件: D00003 --20件: 6, 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 168, 193, 226, 271, 294, 299, 330
1165Oxygen 40 %1件: Oxygen1件: D00003 --1件: 85
1166Oxygen flow at the optic nerve head measurement1件: Oxygen1件: D00003 --1件: 19
1167Oxygen saturation1件: Oxygen1件: D00003 --1件: 84
1168Oxygen supplementation1件: Oxygen1件: D00003 --1件: 86
1169Oxygen, liquid1件: Oxygen1件: D00003 --2件: 86, 88
1170Oxymatrine1件: Oxymatrine---1件: 37
1171Oxymizer® compared to CNC----1件: 85
1172Oxynorm----1件: 298
1173Oxytocin1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬6件: 6, 72, 127, 193, 206, 226
1174Oxytocin (OXT) continuous1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 193
1175Oxytocin 24IU1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 206
1176Oxytocin 48IU1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 206
1177Oxytocin nasal spray1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 72
1178OXYTOCIN SYNTHETIC1件: Oxytocin1件: D00089 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 6
1179Oyster1件: Oyster---1件: 84
1180Ozanezumab1件: Ozanezumab1件: D10331 1件: RTN4 💬1件: Alzheimer disease 💬1件: 2
1181Ozanimod1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 96, 97
1182Ozanimod 0.5 mg1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
1183Ozanimod 1 mg1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
1184Ozanimod HCI1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
1185Ozanimod HCL1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
1186Ozanimod hydrochloride1件: Ozanimod1件: D10968 5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 96, 97
1187Ozone1件: Ozone---3件: 49, 51, 226
1188Ozoralizumab1件: Ozoralizumab1件: D09944 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46